The cancer testis antigen (CTA) lactate dehydrogenase C (LDHC) is a promising anti-cancer target with tumor-specific expression, immunogenicity and a role in metabolic reprogramming. Interrogation of the TCGA breast cancer cohort demonstrates upregulation of LDHC expression, conferring unfavorable prognosis. Although the role of LDHC is well characterized in spermatocytes, its role in tumors remains largely unknown. We investigated whether LDHC, in analogy with other CTAs, is involved in regulating genomic stability and may be targeted to affect tumor cellular fitness. Silencing LDHC in four breast cancer cell lines significantly increased the presence of giant cells and nuclear aberrations, DNA damage and apoptosis. Further analysis of LDHC silenced cells demonstrated aberrant cell cycle progression with differential expression of cell cycle checkpoint and DNA damage response regulators, resulting in a shortened G1 phase, intra-S checkpoint override and G2/M checkpoint adaptation. In addition, LDHC silencing induced microtubule destabilization, culminating in increased mitotic catastrophe and reduced long-term survival. Notably, cisplatin and olaparib treatment further reduced survival of LDHC silenced cells. In conclusion, this study supports the therapeutic potential of targeting LDHC to mitigate cancer cell survival, and to improve sensitivity to DNA damaging and DNA damage repair inhibiting agents.